Supported with 44 data exhibits and spread across 97 pages, theGlobal Acute Coronary Syndrome
(ACS) Market 2015-2019 report is available at http://www.
Major Points in Table of Contents of Acute Coronary Syndrome
- US Drug Forecast and Market Analysis to 2023 Research Report:
Frequency of acute coronary syndrome
in patients presenting to the emergency department with chest pain after methamphetamine use.
Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes
SAN FRANCISCO -- People infected with HIV are diagnosed with acute coronary syndromes
an average of 11 years earlier than are their HIV-negative counterparts, Priscilla Hsue, M.
For the cross-sectional study, conclusions were based on the 490 usable responses submitted by 1,217 patients who were treated for acute coronary syndrome
at the university from July 1999 to November 2002.
Findings from the sub-analysis, Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndrome
from the EXAMINE Trial, demonstrated no effect on rates of CV mortality hazard ratio (HR)= 0.
In the updated guidelines - entitled Management of acute coronary syndromes
in patients presenting without persistent ST-segment elevation - prasugrel was recommended regardless of a patient's genetic status(1), and the guidelines state prasugrel does not appear to be affected by CYP inhibitors, including proton pump inhibitors(2).
Acute coronary syndrome
is one of the most severe forms of heart disease, and is the most frequent cause of morbidity and mortality in the developed world.
Measuring the serum level of cardiac troponin T can help determine if a patient with end-stage renal disease has acute coronary syndrome
com/research/xtx4wn/global_acute) has announced the addition of the "Global Acute Coronary Syndrome
Drug Pipeline Capsule - 2012 Update" report to their offering.
The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the Acute Coronary Syndrome
market, both medically and financially.
Food and Drug Administration (FDA) issued complete response letters (CRLs) regarding supplemental New Drug Applications (sNDAs) for the use of XARELTOA (rivaroxaban), an oral anticoagulant, to reduce the risk of secondary cardiovascular events defined as heart attack, stroke or death in patients with acute coronary syndrome
(ACS) and to reduce the risk of stent thrombosis in the same population, in combination with standard antiplatelet therapy.
Approximately 100,000 patients develop an acute coronary syndrome
(ACS) and elect to undergo PCI every year in Japan -- where Plavix(R) is now the first drug approved in this indication --, the largest number of patients in the world outside of the United States.
SAN FRANCISCO -- An ECG mapping device improved the diagnosis of acute coronary syndrome
, compared with standard ECG, and provided information that could help with treatment, said Gregory J.